Knights of Columbus Asset Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-16,158	Closed	-$10.2M	–	326
2021 Q4	$10.2M	Sell	16,158 -612	-4%	-$376K	0.82%	17
2021 Q3	$10.1M	Buy	16,770 +3,252	+24%	+$2.02M	0.91%	13
2021 Q2	$7.55M	Buy	13,518 +124	+0.9%	+$62.8K	0.7%	19
2021 Q1	$6.34M	Buy	13,394 +2,799	+26%	+$1.36M	0.62%	32
2020 Q4	$5.12M	Buy	+10,595	New	+$5.72M	0.54%	45

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Knights of Columbus Asset Advisors's REGN Position: Q1 2022 in Review

Knights of Columbus Asset Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2022, closing a stake of 16,158 shares — an estimated $10.2M sold.

Knights of Columbus Asset Advisors first reported a position in REGN in Q4 2020 and held it in 5 quarters. The position peaked at $10.2M in Q4 2021. 1,095 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

Knights of Columbus Asset Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Knights of Columbus Asset Advisors sold 16,158 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $10.2M.
Knights of Columbus Asset Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2020 and held it in 5 quarters.
Knights of Columbus Asset Advisors's Regeneron Pharmaceuticals position peaked at $10.2M in Q4 2021.
1,095 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on Knights of Columbus Asset Advisors's 13F filing for Q1 2022, filed 16 May 2022.